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Selective regulation of aromatase expression for drug discovery* 
Robert W. Brueggemeier , Bin Su , Michael V. Darby , Yasuro Sugimoto 
Introduction 
Estrogens are biosynthesized from androgens by the 
cytochrome P450 enzyme complex called aromatase [1,2]. 
The highest levels of enzyme are present in the ovaries of pre-
menopausal women, in the placenta of pregnant women, and in the 
peripheral adipose tissues ofpostmenopausal women and of men. 
Aromatase activity has also been demonstrated in breast tissue 
in vitro [3-5 ], and expression of aromatase is highest in or near 
breast tumor sites [4,6]. Regulation of aromatase in various tissues 
is complex, and several tissue-specific promoter regions have been 
identified upstream from the CYP19 gene [2,7,8]. Promoter 1.1 is 
the major promoter used in placental tissues and is the farthest 
upstream. The PII promoter is utilized in the ovary and in breast 
cancer tissues and contains a cAMP response element. Promoters 
1.3, 1.4, 1.6, and 1.7 are the promoters used in extraglandular sites. 
Promoter PI.4 is the primary promoter used in normal adipose 
tissue and is responsive to glucocorticoids and cytokines such as 
IL-1 f3, IL-6 and TNFa. 
In breast cancer tissues, an increased expression of aromatase 
cytochrome P450 is observed due to utilization of multiple pro-
moter regions for gene expression. In the normal breast cells, 
aromatase expression is primarily derived by the tissue-specific 
promoter 1.4 for transcription, whereas expression from breast can-
Fig. 1. Drug design approach for novel sulfonanilides as selective aromatase modulators.
cer patients is primarily derived from the utilization of promoter
I.3 and promoter II [9]. As a result of the use of the alternate
promoters, the regulation of estrogen biosynthesis switches from
one controlled primarily by glucocorticoids and cytokines to a
promoter regulated through cAMP-mediated pathways, and the
prostaglandin PGE2 increases intracellular cAMP levels and stim-
ulates estrogen biosynthesis [9].
Research in our laboratories focuses on the development of
novel therapeutic interventions targeting tissue-speciﬁc expres-
sion of aromatase. Our small molecule approach utilizes drug
discovery technologies to develop novel sulfonanilides as selective
agents regulating aromatase expression [10–14]. A secondpharma-
cological approach involves the development of siRNA molecules
that interfere with aromatase expression [10]. This manuscript
reviews our recent publications in this area and presents prelimi-
nary results.
Novel sulfonanilide analogs for suppression of
aromatase expression and activity
Previously, we demonstrated that COX-2 inhibitors nimesulide,
N-(2-phenoxy-4-nitrophenyl)-methanesulfonamide, and NS-398,
N-(2-cyclohexyloxy-4-nitrophenyl)-methanesulfonamide, sup-
press aromatase activity in breast cancer cells by suppressing
aromatase transcription [15]. Interestingly, these two agents share
very similar chemical structures (Fig. 1). In addition, introduction
of a methyl group at the N atom of the sulfonamide group to
the COX-2 inhibitor nimesulide resulted in no COX-2 inhibitory
activity [16]. This structural modiﬁcation was utilized in our drug
design of novel sulfonanilide derivatives of nimesulide andNS-398.
The nitro group at the 4 position of the sulfonanilides was retained
and modiﬁcations of the sulfonamide and of the 2-position group
were made to generate the targeted libraries of new compounds
(Fig. 1) [11].
Evaluations of the synthetic compoundswereperformed inboth
SK-BR-3 breast cancer cells, which produce aromatase expression
from promoter II and I.3 mediated by cAMP [12]. SK-BR-3 cells
grown in deﬁned media containing DMEM/F12 media, 1.0mg/mL
human albumin, 5.0mg/L human transferin and 5.0mg/L bovine
insulin were treated with the synthetic compounds for 24h. Cells
were then incubated for 3h with fresh media, and aromatase
activity measured by the tritiated water release assay [12]. Many
compounds signiﬁcantly decreased aromatase activity in SK-BR-3
cells at 2.5M (Fig. 2), and those compounds with enhanced activ-
ities were further evaluated for selective regulation of aromatase
expression.
Dose–response studies of the effects on aromatase activitywere
performed in SK-BR-3 cells on six compounds. All six compounds
exhibited dose–response curves for suppression of aromatase
activity (Fig. 3), and the corresponding IC50 values range from
0.33 to 2.68M. Furthermore, real-time PCR experiments demon-
strated that these compounds signiﬁcantly decreased CYP19 gene
expression at 5M in SK-BR-3 cells [12]. The results of the cellular
aromataseassaydemonstrated that aonecarbonextensionat the2-
position of nimesulide results in signiﬁcant increase in suppression
of aromatase in breast cancer cells compared with nimesulide.
A combinatorial chemistry approach was used to generate
diversely substitutednimesulidederivatives (Fig. 4) byparallel syn-
Fig. 2. Suppression of aromatase activity by novel sulfonanilides in SK-BR-3 cells
(adapted from [12]). SK-BR-3 cells were treated with compounds (2.5M) and aro-
matase activity was measured. The value of 100% is equal to 0.03pmol/h/106 cells;
n=3.
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Fig. 3. Dose–response curves and IC50 values for selected novel sulfonanilides (adapted from [12]). The value of 100% is equal to 0.03pmol/h/106 cells. Each data point
represents the mean results of three independent determinations, and the data were statistically analyzed by a nonlinear regression analysis method.
thesis [13,14]. This innovative technology of producing libraries
of structurally related compounds is particularly beneﬁcial in the
step of lead optimization, facilitating structural modiﬁcations of
a lead scaffold to enhance pharmacological activity, improve phar-
macokinetic properties, and/or reduce unwanted side effects. Their
pharmacological evaluation as agents for suppression of aromatase
activity in breast cancer cells was further explored in the SK-BR-3
breast cancer cell lines and inMCF-7 cells transfectedwith the aro-
matase gene. A ligand-based pharmacophoremodel identiﬁed four
chemical features critical for biological activity, namely, the central
aromatic ring, onehydrophobic function (Fig. 4, positionA) and two
hydrogen bond acceptors (Fig. 4, positions C and D).
RNA interference of aromatase expression
Newly developed RNA interference (RNAi) technology was uti-
lized to further probe the interactions between aromatase and
cyclooxygenases in breast cancer [10]. RNAi technology permits
transient suppression of the levels of endogenous proteins inmam-
malian cells by enhancing the degradation of target mRNA. One
RNAi approach involves transfection of 21–23 nucleotide double-
stranded, short interfering RNAs (siRNA) into mammalian cells.
These siRNAs are then incorporated into the RNA-inducing silenc-
ing complex (RISC), and RISC unwinds the siRNA duplex using
ATP. The unwound, single-stranded antisense strand guides RISC
to mRNA that has a complementary sequence, and the complex
results in the endonucleolytic cleavage of the target mRNA.
Short interfering RNAs (siRNA) were designed to target either
human CYP19mRNAor human COX-2mRNA. The effects of siAROM
and siCOX2 on aromatase enzyme activity in SK-BR-3 cells were
examined (Fig. 5). The transfection of siAROM resulted in sup-
pression of basal levels of aromatase activity by greater than 90%
comparedwith cells transfectedwith anonspeciﬁc control siRNAor
Fig. 4. Targeted librariesofnovel sulfonanilideswithmodiﬁcationsatpositionsA–D.
Fig. 5. Effect of PGE2 on suppression of aromatase activity by siRNAs in SK-BR-3
cells [10]. The value of 100% is equal to 0.025pmol/h/106 cells; n=4.
untreated cells. Also shown in this ﬁgure, the siCOX2 also resulted
in suppression of aromatase activity by approximately 67%. Fur-
thermore, the administration of PGE2 to cells treated with the
siRNAs results in antagonism of only the siCOX2 and restores aro-
matase activity to untreated levels (Fig. 5) [10].
The effect of the siAROM on aromatase enzyme activity in sev-
eral cancer cells was also examined (Fig. 6). The siAROM silenced
aromatase enzyme activity by greater than 90% in the SK-BR-3
human breast cancer cell line, in MCF-7 human breast cancer cells
transfected with the aromatase gene, and in the JAr human chorio-
carcinoma cell line. The suppression of aromatase enzyme activity
was greater than 80% in the JEG-3 human choriocarcinoma cell line.
Fig. 6. Suppression of aromatase activity by siRNAs in various human cancer cell
lines. The value of 1.0 is equal to 0.025pmol/h/106 cells; n=3.
209
Discussion
Two pharmacological approaches of novel therapeutic inter-
ventions targeting tissue-speciﬁc expression of aromatase have
been recently developed in our laboratories. Our small molecule
approach utilizes drug discovery technologies to develop novel sul-
fonanilides as selective agents regulating aromatase expression.
Targeted synthetic libraries of novel sulfonanilide analogs, derived
from COX-2 inhibitiors nimesulide and NS-398, decreased CYP19
mRNAexpressionandsuppressedaromataseenzymeactivity inSK-
BR-3 breast cancer cells in a dose dependentmanner. Furthermore,
N-methyl sulfonanilide analogs without COX-2 inhibitory activity
showed similar effects of decreased CYP19 mRNA expression and
suppression of aromatase activity. Thus, these results suggest that
the novel sulfonanilides targeting aromatase expression may be
valuable tools for selective regulationof aromatase inbreast cancer.
Investigations using RNA interference (RNAi) technology con-
ﬁrmed the interactions between aromatase and cyclooxygenases
in breast cancer. Short interfering RNAs (siRNA) were designed
against either human CYP19 mRNA or human COX-2 mRNA. Treat-
ment of breast cancer cells with siAROM suppressed CYP19 mRNA
and aromatase enzyme activity. Treatment with siCOX2 down-
regulated the expression of COX-2 mRNA and also resulted in
suppression of aromatase mRNA. The administration of PGE2 to
cells treated with the siRNAs results in antagonism of only the
siCOX2 and restores aromatase activity to untreated levels. Finally,
the siAROMwas also very effective in silencing aromatase enzyme
activity in human breast cancer cells in culture and in human chori-
ocarcinoma cells in culture.
The regulation of aromatase in breast cancer involves com-
plex autocrine and paracrine interactions, resulting in signiﬁcant
consequences on the pathogenesis of hormone-dependent breast
cancer. The breast cancer tissue microenvironment can inﬂuence
the extent of estrogen biosynthesis and metabolism, resulting in
altered levels of hormonally active estrogens and therefore inﬂu-
encing breast tumor development and growth. Furthermore, novel
sulfonanilides and various RNAi technologies targeting aromatase
expression may be valuable tools for selective regulation of aro-
matase in breast cancer and could be developed into the ﬁrst
generation of Selective Aromatase Modulators for the treatment
of hormone-dependent breast cancer.
Acknowledgements
This work was supported by the National Institutes of Health
(NIH) Grant R01 CA73698 (R.W.B.), the USAMRMC Breast Cancer
Program Grant W81XWH-08-1-0521, and The Ohio State Univer-
sity Comprehensive Cancer Center Breast Cancer Research Fund.
References
[1] E.R. Simpson, M.S. Mahendroo, G.D. Means, M.W. Kilgore, M.M. Hinshelwood,
S. Graham-Lorence, B. Amarneh, Y. Ito, C.R. Fisher, M.D. Michael, Aromatase
cytochrome P450, the enzyme responsible for estrogen biosynthesis, Endocr.
Rev. 15 (1994) 342–355.
[2] E.R. Simpson, C. Clyne, G. Rubin, W.C. Boon, K. Robertson, K. Britt, C. Speed, M.
Jones, Aromatase—a brief overview, Annu. Rev. Physiol. 64 (2002) 93–127.
[3] V.H. James, J.M. McNeill, L.C. Lai, C.J. Newton, M.W. Ghilchik, M.J. Reed, Aro-
matase activity in normal breast and breast tumor tissues: in vivo and in vitro
studies, Steroids 50 (1987) 269–279.
[4] W.R. Miller, J. O’Neill, The importance of local synthesis of estrogen within the
breast, Steroids 50 (1987) 537–548.
[5] M.J. Reed, A.M. Owen, L.C. Lai, N.G. Coldham, M.W. Ghilchik, N.A. Shaikh, V.H.
James, In situ oestrone synthesis in normal breast and breast tumour tissues:
effect of treatment with 4-hydroxyandrostenedione, Int. J. Cancer 44 (1989)
233–237.
[6] S.E. Bulun, T.M. Price, J. Aitken, M.S. Mahendroo, E.R. Simpson, A link between
breast cancer and local estrogen biosynthesis suggested by quantiﬁcation of
breast adipose tissue aromatase cytochrome P450 transcripts using competi-
tive polymerase chain reaction after reverse transcription, J. Clin. Endocrinol.
Metab. 77 (1993) 1622–1628.
[7] E.R. Simpson, M.S. Mahendroo, G.D. Means, M.W. Kilgore, C.J. Corbin, C.R.
Mendelson, Tissue-speciﬁc promoters regulate aromatase cytochrome P450
expression, Clin. Chem. 39 (1993) 317–324.
[8] Y. Zhao, V.R. Agarwal, C.R. Mendelson, E.R. Simpson, Transcriptional regula-
tion of CYP19 gene (aromatase) expression in adipose stromal cells in primary
culture, J. Steroid Biochem. Mol. Biol. 61 (1997) 203–210.
[9] Y. Zhao, V.R. Agarwal, C.R. Mendelson, E.R. Simpson, Estrogen biosynthesis
proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to
activation of promoter II of the CYP19 (aromatase) gene, Endocrinology 137
(1996) 5739–5742.
[10] R.W Brueggemeier, B. Su, Y. Sugimoto, E.S. Diaz-Cruz, D.D. Davis, Aromatase
and COX in breast cancer: enzyme inhibitors and beyond, J. Steroid Biochem.
Mol. Biol. 106 (2007) 16–23.
[11] B. Su, E.S. Diaz-Cruz, S. Landini, R.W. Brueggemeier, Novel sulfonanilide ana-
logues suppress aromatase expression and activity in breast cancer cells
independent of COX-2 inhibition, J. Med. Chem. 49 (2006) 1413–1419.
[12] B. Su, S. Landini, D.D. Davis, R.W. Brueggemeier, Synthesis and biological evalu-
ation of selective aromatase expression regulators in breast cancer cells, J. Med.
Chem. 50 (2007) 1635–1644.
[13] B. Su, R. Tian, M.V. Darby, R.W. Brueggemeier, Novel sulfonanilide analogs
decrease aromatase activity in breast cancer cells: synthesis, biological evalu-
ation, and ligand-based pharmacophore identiﬁcation, J Med. Chem. 51 (2008)
1126–1135.
[14] B. Su, M.V. Darby, R.W. Brueggemeier, Synthesis and biological evaluation of
novel sulfonanilide compounds as antiproliferative agents for breast cancer, J.
Comb. Chem. 10 (2008) 475–483.
[15] E.S. Diaz-Cruz, C.L. Shapiro, R.W. Brueggemeier, Cyclooxygenase inhibitors
suppress aromatase expression and activity in breast cancer cells, J. Clin.
Endocrinol. Metab 90 (2005) 2563–2570.
[16] F. Julemont, L. de, X.C. Michaux, J. Damas, C. Charlier, F. Durant, B. Pirotte, J.M.
Dogne, Spectral and crystallographic study of pyridinic analogues of nime-
sulide: determination of the active form of methanesulfonamides as COX-2
selective inhibitors, J. Med. Chem. 45 (2002) 5182–5185.
Post-print standardized by MSL Academic Endeavors, the imprint of the Michael Schwartz Library at Cleveland State University, 2017.
210
